Managing Your SBIR/STTR Award Effectively

ADAM SORKIN, MEM, MSE, PE

Small Business Policy Manager SEED (Small business Education & Entrepreneurial Development)

OFFICE OF EXTRAMURAL RESEARCH | OFFICE OF THE DIRECTOR | NATIONAL INSTITUTES OF HEALTH

This presentation may include presenter's notes.



Agenda

- 2024 NIH SBIR/STTR Program Updates
- Panel
 - Roger Miller, PhD SBIR/STTR Program Coordinator (NIDCD)
 - Kari Ashmont, PhD Translational Team Lead, Office of Program Evaluation and Strategic Partnerships (NIBIB)
 - Callie Prassinos Branch Chief/ Contracting Officer, Office of Acquisitions (NIAID)
 - Jonelle Soeffing Operations Office, Investigations Branch, HHS Office of Inspector General

• Q&A



Webinar Goals

- Discuss best practices for SBIR and STTR award (Grants and Contracts) management
 - Recipient Expectations
 - Points of contact for technical and administrative concerns
 - Avoiding and resolving problems
- Avoiding Fraud, Waste and Abuse
 - Fraud Awareness and Consequences
 - Case Studies
 - How to report FWA concerns



2024 SBIR/STTR Update - Foreign Risk Assessment

New Requirement from the SBIR and STTR Extension Act of 2022

- For applications submitted for due dates on or after September 5, 2023: NIH is required to assess security risk (prior to issuing an award) including: Cybersecurity practices, Patent analysis, Employee analysis, Foreign ownership, Financial Ties and Obligations
- Disclosure is required using the <u>Required Disclosures of Foreign Affiliations or Relationships to Foreign</u> <u>Countries Form</u>

Policy References

- NOT-OD-24-029: <u>Clarification of Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-</u> award and Post-Award Requirements
- NOT-OD-24-149: Prior Approval Requirement for Changes to Domestic Subawards for the SBIR and STTR Programs
- For Information and Case Studies: <u>Foreign Disclosure and Risk Management webpage</u>



Foreign Disclosure: Post-Award Reporting Requirements

For awards covered by this policy (competitive application submitted for due date on or after September 5, 2023):

- Recipients are responsible for monitoring their relationships with foreign countries of concern post-award, for any changes that may impact previous disclosures
- SBCs receiving an award under the SBIR/STTR program are required to submit an updated disclosure form to report any of the following changes to NIH
 - any change to a disclosure on the disclosure form;
 - any material misstatement that poses a risk to national security; and
 - any change of ownership, change to entity structure, or other substantial change in circumstances of the SBC that NIH determine poses a risk to national security.
- Regular, annual updates are required at the time of all SBIR/STTR annual, interim, and final Research Performance Progress Reports (RPPRs).
- For changes that occur between RPPR submissions, updated disclosure forms are required within 30 days.







Tips for Efficiently Managing Your SEED Award

Roger Miller, Ph.D. SBIR/STTR Program Coordinator (NIDCD) National Institute on Deafness and Other Communication Disorders, National Institutes of Health

millerr@nidcd.nih.gov

December 2024







eRA Commons: Essential nexus for official grant updates.

eRA Commons account / website is essential to:

- Download Summary Statement
- Upload Just in Time (JIT) information
- Verify HOM email address
 - Should match email address on face page of an application.
 - The official definition is "PI Home Office Address."
 - NIH's automated business systems will use this for JIT and other requests.
 - Best practice: establish *.com address, (not *.edu).

Download Notice of Award (NoA)

- Emailed to the Institutional Profile.
- Principal investigator (PI) and Signing Official (SO) can view NoA from the Status Information screen.

<u>https://www.era.nih.gov/help-tutorials/era-commons/improved-visual.htm</u> <u>https://www.era.nih.gov/erahelp/Commons/Commons/NavigationAndUI.htm</u> <u>https://www.era.nih.gov/docs/Commons_UserGuide.pdf</u>



7



Download Notice of Award (NoA) from eRA

XXXX

- Award Number (11)
- Principal Investigator (7)
- Authorized Official (8)
- **Grants Management Officer (9)**
- Program Officer (10)
- Email communications should:
- Sent from PI's HOM email.
- Subject line with grant number.
- Official responses forwarded though AO
- Include both PO and GMS on official requests.
- Results will be uploaded into the official grant file.

End Date

- No Cost Extension (NCE) possible for up to 12 months
- Link available in eRA 90 days before end date.
- The F-RPPR and I-RPPR must be submitted via eRA Commons no later than 120 calendar days from the period of performance end date.
- www.era.nih.gov/recipients/submit-no-cost-ext.htm
- www.grants.nih.gov/grants/guide/notice-files/NOT-OD-11-098.html

Operating Division	Ith and Human Services I	FAIN# XXXX Federal Aw XX/X	
Recipient Information	Federal Award Information		
1. Recipient Name Name of Recipient Address Line 1	11. Award Number XXXXXXXXXXXXXXX		
Address Line 2 City, State, XXXXX-XXXX	12. Unique Federal Award Identification Number (FAIN)		
2. Congressional District of Recipient XX	13. Statutory Authority		
3. Payment System Identifier (ID) XX-XXXXXXX	XX XXX XXXX XXX XXX		
4. Employer Identification Number (EIN) XX-XXXXXXX	14. Federal Award Project Title XXXX		
5. Data Universal Numbering System (DUNS) XX-XXX-XXXX			
6. Recipient's Unique Entity Identifier	15. Assistance Listing Number XX.XXX		
Project Director or Principal Investigator Name Title	16. Assistance Listing Program Title XXXX		
email@email.com PI			
6. Authorized Official Name	17. Award Action Type XXXX		
Title AO email@email.com xXX-XXX-XXXX	18. Is the Award R&D? XXXX		
Federal Agency Information	Summary Federal Award Financial		n
	19. Budget Period Start Date XX/XX/XXXX – End Date	XX/XX/XXXX	
9. Awarding Agency Contact Information Name	20. Total Amount of Federal Funds Obligated by this Acti	-	0
Title GMO	20a. Direct Cost Amount 20b. Indirect Cost Amount	s s	0
Operating Division Name email@email.com			
XXX-XXX-XXXX	21. Authorized Carryover	S	0
	22. Offset	S	0
	23. Total Amount of Federal Funds Obligated this budget p		0
10. Program Official Contact Information	24. Total Approved Cost Sharing or Matching, where app		0
Name of Program Official	25. Total Federal and Non-Federal Approved this Budget	Period \$	0
Title PO Operating Division Name	26. Project Period Start Date XX/XX/XXXX - End Date		J
email@email.com XXX-XXX-XXXX	27. Total Amount of the Federal Award including Approve Cost Sharing or Matching this Project Period	d Ş	0
	28. Authorized Treatment of Program Income XXXX		
	29. Grants Management Officer - Signature Signature		



NoA Indicates Funding and Restrictions

Funding level

					-	-
IC	CAN	2022	2023	2024	2025	2026
DC		\$,	\$.	\$	\$	\$

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Reductions from requested costs will be reflected here.

Funds provided as grant in aid.

- If funds are indicated for future years, Research Performance Progress Report will be needed.
- Indirect cost rate will be indicated, and it may not be what was requested.

Award Conditions

Animal studies?

Was the award restricted?

Human studies? Was the award restricted?

Clinical Trial?

Prepare to register at clinicaltrials.gov

1.4. Clinical Trial Questionnaire *				
1.4.a. Does the study involve human participants?	•	Yes	0	No
1.4.b. Are the participants prospectively assigned to an intervention?	•	Yes	0	No
1.4.c. Is the study designed to evaluate the effect of the intervention on the participants?	•	Yes	О	No
1.4.d. Is the effect that will be evaluated a health-related biomedical or behavioral outcome?	•	Yes	0	No
1.5. Provide the ClinicalTrials.gov Identifier (e.g. NCT87654321) for this trial, if applicable				

The grantee or principal investigator must register the applicable clinical trial at <u>clinicaltrials.gov</u> no later than 21 days after enrolling the first subject. Registration consists of submitting four categories of data elements: (1) descriptive information, (2) recruitment information, (3) location and contact information, and (4) administrative information.



Annual, Interim, and Final Research Performance Progress reports document the grantee recipient's accomplishments Show compliance with terms of award. Must be submitted electronically through eRA Commons.

Submit via eRA 120 days before the end of the "period of performance."

B.1 WHAT ARE THE MAJOR GOALS OF THE PROJECT? Paste relevant section of specific aims from application, don't modify.

B.2 WHAT WAS ACCOMPLISHED UNDER THESE GOALS?

Upload PDF about two pages in length. Organize results by Aims / milestones; state no changes in aims. Include photographs of prototype, circuit boards, software user interface. Provide graphs with preliminary data acquired. Describe challenges and efforts taken to overcome issues.

...Supply chain delays

...enrolment of humans subjects slower than anticipated

... expect to request a 12 month no cost extension

C.1 PUBLICATIONS

Provide MyNCBI Public Access Compliance Report.

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-079.html https://www.nlm.nih.gov/pubs/techbull/jf10/jf10_issue.pdf https://www.nlm.nih.gov/pubs/techbull/nd12/nd12_mvncbi_pdf.html

Human Subjects Enrollment Table

Is enrollment on track based on plans noted in the application?

https://grants.nih.gov/sites/default/files/rppr_instruction_guide.pdf https://www.era.nih.gov/sites/default/files/RPPRs-Who-Does-What.pdf https://www.era.nih.gov/recipients/submit-no-cost-ext.htm

Publications Reported for this Reporting Period

NIH Public Access Compliance	Citation
In process at NIHMS	Lee J, Sharei A, Sim WY, Adamo A, Langer R, Jensen KF, Bawendi MG. Nonendocytic Delivery of Functional Engineered Nanoparticles into the Cytoplasm of Live Cells Using a Novel, High-Throughput Microfluidic Device. Nano Lett. 2012 Nov 16;PubMed PMID: 23145796; NIHMSID: 421917.
Complete	Song JW, Daubriac J, Tse JM, Bazou D, Munn LL. RhoA mediates flow- induced endothelial sprouting in a 3-D tissue analogue of angiogenesis. Lab Chip. 2012 Oct 30;12(23):5000-6. PubMed PMID: 23073300; PubMed Central PMCID: PMC3490212.
In process at NIHMS	Wei H, Bruns OT, Chen O, Bawendi MG. Compact zwitterion-coated iron oxide nanoparticles for in vitro and in vivo imaging. Integr Biol



Program staff verify that funds are spent *within scope* of the peer-reviewed application



Phase I Award: Feasibility Study / Proof of Concept (POC)

- Total costs capped at \$306,872 total costs.
- Project Period: 6 months 1 year

Maintain focus on POC.

- Pilot data not required for Phase I application.
- Proof of Concept data absolutely required for Phase II application.

Phase II Award: Full Research & Development

- Total costs over two years capped at \$2,045,816 total costs.
 - See budget wavier topics for each NIH IC.
- Project Period: varies, 2+ years.
- Product development complete at end of Phase II
 - IP Licensing strategy? Provide letters of support from potential licensee(s).
 - Direct vending/customer support for novel product.
- Technical and Business Assistance (TABA)



Phase III Commercialization

- Commercialization plan provided with application.
- Consider NIH SEED Innovator Consultation.

Marketing costs are outside the scope of SEED funding.

Commercialization Readiness Pilot (CRP) can help.

Funds spent as described in application.



PI may request NIH SEED Innovator Consultation.



Business Consult

Seeking insights about your company's next steps? Talk to an Entrepreneur in Residence!



Intellectual Property Consult

Want more information about patenting and/or licensing issues to advance your product or service? Ask for an IP consult.



Pitch Review Consult

Heading to a meeting? Talking to an investor? Get feedback before your pitch!



Regulatory Consult

Not sure if you need to or when to talk with FDA? SEED's regulatory affairs experts can help.



Reimbursement Consult

Who is actually going to pay (and how much) for your product? Ask a reimbursement expert.



SOW Consult

Need to outsource expertise or research activities? Clarify your ask with an Statement of Work consult.

Request A 1-hour Consultation:







Understanding Reporter.NIH.gov and the Award Lifecycle



A Back to Search Results	Study of the New HDA Tauopathies	C6i SW-100 as a Treatment for
🗎 Description 🔶	Project Number	Contact PI/Project Leader
Details	1R41AG058283-01	KOZIKOWSKI, ALAN P.Other Pls
👬 Sub-Projects		FIS
Publications	Description	
♀ Patents		
D Outcomes	Abstract Text	
L Clinical Studies		other tauopathies are medical problems gro dical care systems world-wide. Alzheimer's
🕮 News and More	5 5 11	ges. Effective disease-modifying treatments et amyloid, but very few have been develope
5 History	disease, cancer and HIV, effe	ective Alzheimer's management will require work by our research team has determined
T Similar Projects	mice that develop tau depos found improved behavioral p phenotype in this model wer inhibitor, SW-100, can more slightly longer half-life and s	cetylase 6 (HDAC6) inhibitor, Tubastatin A (its by 3 mo and forebrain atrophy by 6 mo o erformance and reduced total tau depositic e not significantly impacted. Here we propo completely rescue the tau phenotype in this ubstantially increased brain permeability that t of TA, but increased CNS penetration. SW-

Description:


• Entry will be copied verbatim from application's abstract.

Sub-Projects	Publications			.≵ E	xport >	Disclaimer
Publications	Journal (Link to PubMed abstract)	Authors	Publication Year	Similar Publications	CitedBy	iCite RCI
Patents	Mercaptoacetamide: A promising zinc-bir	nding group for the discovery of s	elective history	e deacetvlase	6 inhibitor	۰ ۹
Outcomes	European journal of medicinal chemistry 2021 Jan 01; 209 112887	Tavares, Maurício T; Kozikowski, Alan P; Shen, Sida	2021	G G	₫ G	iCite 3.4
Clinical Studies	Tetrahydroquinoline-Capped Histone Dea Marie-Tooth Type 2A Mouse Model.	cetylase 6 Inhibitor SW-101 Ame	liorates Patholo	gical Phenoty	/pes in a Ch	narcot-
News and More	Journal of medicinal chemistry 2021 04 22; 64 (8 4810-4840	 Shen, Sida; Picci, Cristina; Ustinova, Kseniya; Benoy, Veronick; Kutil, 	2021	ία	血	

Publications:

"... all investigators funded by the NIH submit or have submitted for them to the National Library of Medicine's PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication."

https://sharing.nih.gov/public-access-policy



Outcomes:

- Entry will be copied verbatim from Final Research Progress Report (FRPPR)
- Use concise and comprehensible language.
- Avoid jargon; write for the general public.
- Do not include proprietary, confidential information, or trade secrets.



www.niaid.nih.gov/grants-contracts/sample-applications#r43r44 Kozikowsky R41AG058283 (2017) https://reporter.nih.gov/search/rRylhktDCU286W6Xt1BsRA/project-details/9463081

Working with NIH to Manage your SBIR/STTR Award

Kari Ashmont, PhD Translational Team Lead | NIBIB NIBIB-SBIR@mail.nih.gov



This presentation may include presenter's notes.

Be Informed!

Read your Notice of Award (NOA) Carefully

- What is the Notice of Award (NoA)?
 - Legal Document issued to notify the organization that an award has been made.
- Why is it important?
 - Budget/Project Periods
 - Funding Commitments
 - Terms and Conditions
 - GMS and Program Official (PO) Contact Information
 - Restrictions <u>funds cannot be spent on restricted items!</u>
 - Closeout Information
- How does award acceptance occur?
 - Draw down or request of funds from the Payment Management System

Review the NIH Welcome Wagon Material and Grants Policy Statement

- Welcome Wagon summarizes key requirements, referrals to important sources of information, and identification of NIH and other <u>Department of Health and Human Services</u> (HHS) offices with responsibility for certain administrative functions
- NIHGPS collates the policy requirements that serve as a term and condition of NIH grant awards

Contact your <u>Grants</u> <u>Management Specialist</u> with questions or concerns!



Prior Approvals

Changes Requiring Prior Approval:

- Change in project scope
- Change in project budget
- Change in approved animal model
- Change in the level of effort of key personnel <u>listed on NoA</u>
- Change in recipient organizational status*
- See <u>Grants Policy Statement 8.1.2</u> for additional items and information

Requesting Prior Approval:

- <u>Prior Approval Module</u>
 - Change in PD/PI
 - No Cost Extensions
 - Carryover requests
- Email requests
 - Sent 30 days before proposed change
 - All requests must come from the Authorized Organizational Representative (AOR) to the GMS with the PO copied

Unsure? Reach out to your PO and GMS!



Eligibility

- Organized as for-profit US business
- Small: 500 or fewer employees, including affiliates
- Work must be done in the US (with few exceptions)
- Individual Ownership:
 - Greater than 50% US-owned by individuals and independently operated <OR>
 - >50% owned and controlled by other business concerns that are >50% owned and controlled by one or more individuals, an Indian tribe, ANC or NHO (or a wholly owned business entity of such tribe, ANC or NHO) <OR>
 - SBIR ONLY: Be a concern which is >50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these

Determined <u>at the time of award-</u>Applicants provide either an <u>SBIR</u> or <u>STTR</u> Funding Agreement Certification

Changes in Eligibility

- Legal action that changes the organizational status of a company
 - Merger
 - Acquisition
 - Successor-in-Interest
- Company can no longer receive additional funds from existing awards, including noncompeting continuation awards and supplements to award
- Company can no longer receive new awards
- <u>NOT-OD-22-143</u>



Lifecycle Certification

- What is Lifecycle Certification?
 - Attestation an awardee continues to meet program-specific requirements
 - PI employment status
 - Work requirement, etc.
- When is Lifecycle Certification Required?
 - Phase I: At the time of receiving final payment or disbursement
 - Phase II: Prior to receiving more than 50% of total award amount and prior to final payment or disbursement.
 - When the F-RPPR and I-RPPRs are due and submitted via eRA Commons
 - o No later than 120 calendar days from the period of performance end date
 - SBIR/STTR recipients should <u>not</u> select the "Nothing to Report" box in Section G.1: Special Notice of Award and Funding Opportunity Announcement Reporting Requirements)
- <u>NOT-OD-19-025</u>



You've been awarded a SBIR Contract! What's next?

Callie Prassinos

Branch Chief/ Contracting Officer, OA, NIAID, NIH

Overview

- Contract and its clauses
- Contract Obligations/ Limitation
- Roles of the Contracting Officer and Contracting Officer's Representative
- Statement of Work
- Contract Changes
- Key Personnel
- Invoice Submission and Payment
- Reporting Requirements/ Deliverables
- Evaluation of Contractor Performance (CPARS)
- Moving to Phase II and Fast track


Contract and its clauses

A contract is a legally binding agreement between the two parties, your organization and the government. There will be specific performance requirements in the statement of work and deliverable schedule with details on due dates and expectation for performance.

Usually, contracts are organized by the following sections:

Cover page - Contract #, Contractor's Name, Dates, Signatures

- Section B Prices, Advance Understandings
- Section C –SOW, Reporting Requirements, Invention Reporting
- Section D Marking
- Section E –Inspection and Acceptance
- Section F Period of Performance, Deliveries
- Section G –Contract Administration
- Section H Special Contract Requirements
- Section I FAR Clauses
- Section J Attachments
- Section K Representations and Instructions





Contract Obligations and Limitations

- The mutual obligations of the Government and the Contractor are established by, and limited to, the written stipulations in the contract document.
- Unless specifically authorized by the Contracting Officer, the Contractor shall not assume any obligations or take any action not specifically required or authorized by the contract.

Roles of the Contracting Officer & Contracting Officer's Representative

CONTRACTING OFFICER'S REPRESENTATIVE (COR)


The COR is responsible for:

- Monitoring technical progress
- Recommending changes in requirements to the Contracting Officer (CO). The COR cannot make any changes to the Statement of Work or reporting requirements, only the CO may do this.
- Interpreting technical performance requirements
- Performing required inspection and acceptances
- Assisting in the resolution of technical problems encountered during performance
- The COR may not authorize increases in the negotiated costs.

CONTRACTING OFFICER (CO)

The CO is the only person with the authority to:

- Direct or negotiate any changes to the Statement of Work
- Modify or extend the period of performance
- Change the delivery schedule
- Change the terms and conditions of the contract.



STATEMENT OF WORK

- The Statement of Work defines the work to be performed under the contract and acts as a framework for what costs are covered under the contract.
- The Contractor should be intimately familiar with all details of the Statement of Work.
- Any changes to the Statement of Work must be approved in writing by the Contracting Officer.
- If the Contractor receives a request from the Government to perform a task or activity that will change the Statement of Work, the Contractor must inform the Contracting Officer before beginning work on this task/activity.

Changes to the Contract

								OMB Approval 2700-00
AMENDA	IENT OF SOLICI	TATIONIAN	DIFICATION	OF CONTRACT		RACT ID COD	E	PAGE OF PAG
2. AMENDMENT/MCD		3. EFFECT		4. REQUISITIONFURCH	N REPER NO.	A	5. PROJ	ECT NO. (# applicable
			ock 16C, below]				N/A	
 ISSUED BY National Instit 		CODE		7. ADMINISTERED BY (#	dher than Alem	6)	CODE	E N/A
DEA, Contrac Room 3214, M 6700-B Rocki	ute of Allergy and Infe t Management Progra ASC 7612 edge Drive) 20892-7612	ctious Disease m	25					
8. NAME AND ADDRE	SS OF CONTRACTOR (Mo. 3	Street, County, Sin	in and ZIP: Code)		()	SA. AMENDN	IENT OF S	OLICITATION NO.
						9B. DATED (SEE ITEM	11)
						10A. MODIFI	CATION O	FCONTRACT/ORDER
						10B. DATED	(SEE ITEN	# 13)
CODE			ALITY CODE			TIONIO		
-				AMENDMENTS OF				
_				r and date specified for re- cified in the solicitation or				Is not extende
YOUR OFFER. If b	by virtue of this amendm	ient you desire :	to change an offer a	PRIOR TO THE HOUR A stready submitted, such o ecclived prior to the openin	hange may	be made by t	telegram (or letter, provided (
	D APPROPRIATION DATA (A							
12. ACCOUNTING AND EIN	SOCC 25.55 13. THIS ITE IT MOD	Vrequited) DOC #300N1. EM APPLIES IFIES THE C	ONLY TO MOD	IN \$ DIFICATIONS OF CO DER NO. AS DESCR ANGES BET FORTH IN ITEM	RIBED IN	S/ORDER		DER NO. IN ITEM 10A.
12. ACCOUNTING AND EIN () A. THIS CHAN B. THE ABO/ FORTH INI C. THIS SUPP	D APPROPRIATION DATA (8 SOCC 25.55 13. THIS IT IT MOD NOE ORDER IS ISSUED PUP E NUMBERED CONTRACT/ ITEM 14, PURSUANT TO TH VLEMENTAL AGREEMENT IS	Treputed) DOC #300N1. EM APPLIES IFIES THE C REMART TO: (Spec ORDER IS MODIFIED E AUTHORITY OF E AUTHORITY OF S ENTERED INTO	CONLY TO MOE CONTRACT/ORE offy suttority) THE CH IED TO REFLECT THE FAR 43.103(b).	DIFICATIONS OF CO DER NO. AS DESCR ANGES BET FORTH IN ITEM ADMINISTRATIVE CHANGES	ONTRACT RIBED IN 14 ARE MADE	S/ORDER	RACTOR	
12. ACCOUNTING AND EIN () A. THIS CHAN B. THE ABO/ FORTH INI C. THIS SUPP	D APPROPRIATION DATA (I SOCC 25.55 13. THIS IT IT MOD IT MOD IN MODER IS ISSUED PUT ITEM 14, PURSUANT TO TH	Treputed) DOC #300N1. EM APPLIES IFIES THE C REMART TO: (Spec ORDER IS MODIFIED E AUTHORITY OF E AUTHORITY OF S ENTERED INTO	CONLY TO MOE CONTRACT/ORE offy suttority) THE CH IED TO REFLECT THE FAR 43.103(b).	DIFICATIONS OF CO DER NO. AS DESCR ANGES BET FORTH IN ITEM ADMINISTRATIVE CHANGES	ONTRACT RIBED IN 14 ARE MADE	S/ORDER	RACTOR	
EIN C. THIS CHAP C. THIS SUP D. OTHER (S) E. IMPORTANT	CAPPROPRIATION DATA (I SOCC 25.55 13. THIS IT IT MOD IT MOD E NUMBERED CONTRACTS IT MOD E NUMBERED CONTRACTS ITEM 14, PURSUANT TO TH NLEMENTAL AGREEMENT IS peedly type of modification and TT: Contractor	Treputed) DOC #300N1. EM APPLIES IFIES THE C REUANT TO: (Spe ORDER IS MOOP RE AUTHORITY OF S ENTERED INTO a withority) is not, is not,	S ONLY TO MOD CONTRACT/ORE of y action(y) THE Ore FAR 43.100(p) PURBUANT TO AUTHO is required to sig	DIFICATIONS OF CO DER NO. AS DESCH ANGES BET FORTH IN THE ADMINISTRATIVE CHANGES BRITY OF:	DNTRACT RIBED IN 14 ARE MADE	CS/ORDER TEM 14. EIN THE CONT ges in paying of copi	RACT OR	
EIN C. THIS CHAP C. THIS SUP D. OTHER (S) E. IMPORTANT	CAPPROPRIATION DATA (I SOCC 25.55 13. THIS IT IT MOD IT MOD E NUMBERED CONTRACTS IT MOD E NUMBERED CONTRACTS ITEM 14, PURSUANT TO TH NLEMENTAL AGREEMENT IS peedly type of modification and TT: Contractor	Treputed) DOC #300N1. EM APPLIES IFIES THE C REUANT TO: (Spe ORDER IS MOOP RE AUTHORITY OF S ENTERED INTO a withority) is not, is not,	S ONLY TO MOD CONTRACT/ORE of y action(y) THE Ore FAR 43.100(p) PURBUANT TO AUTHO is required to sig	DIFICATIONS OF CO DER NO. AS DESCH ANGES BET FORTH IN ITEM ADMINISTRATIVE CHANGES 2RITY OF:	DNTRACT RIBED IN 14 ARE MADE	CS/ORDER TEM 14. EIN THE CONT ges in paying of copi	RACT OR	spristion date, etc.) SET
		Treputed) DOC #300N1. EM APPLIES IFIES THE C REUANT TO: (Spe ORDER IS MOOP RE AUTHORITY OF S ENTERED INTO a withority) is not, is not,	SONLY TO MOE CONTRACT/OR of extent) THE OF PORT AS 100(0) PURELANT TO AUTHOR is required to si UCF and/or Analogs, N	DIFICATIONS OF CO DER NO. AS DESCH ANGES BET FORTH IN THE ADMINISTRATIVE CHANGES BRITY OF:	ONTRACT RIBED IN 14 ARE MADE (puch so offer (puch so offer d) return (pict mether w	CS/ORDER TEM 14. EIN THE CONT ges in paying of copi	RACT OR	spristion date, etc.) SET
E ACCOLIMING AND EIN () A THIS CHAP FORMEN C THIS UNP C THIS UNP	DAMPROMISSION BATH SOCC 25.55 13. THIS ITI IT MOD WE ONCE IN BUILD THIS ITI MOD WE ONCE IN BUILD THIS IN ANY ANY ANY ANY ANY ANY ANY ANY INVESTIGATION ANY ANY ANY ANY ANY ANY ANY ANY ANY INVESTIGATION ANY ANY ANY ANY ANY ANY ANY ANY ANY AN	Treputed) DOC #300N1. EM APPLIES IFIES THE C REUANT TO: (Spe ORDER IS MOOP RE AUTHORITY OF S ENTERED INTO a withority) is not, is not,	SONLY TO MOD CONTRACT/ORD of extent) THE de Frank ds 100(s). Frank ds 100(s). Frank ds 100(s). Frank ds 100(s). Frank ds 100(s). Frank ds 100(s). Frank ds 100(s).	DIFICATIONS OF CI DER NO. AS DESCR MARGES BET FORTH IN THE ADMINISTRATIVE CHANGES BITTY OF: gn this document an app this document an	ONTRACT RIBED IN 14 ARE MADE (auch so chew d return) d return) d return)	CS/ORDER TEM 14. EIN THE CONT ges in paying of copi	RACT OR	spristion date, etc.) SET
	DAMPROMISSION BATH AND A STATE	Trequest) DOC #300M1 DOC #300M1 DIFIES THE C MAPPLIES THE C RELATE NOT COMPANY OFFICE IS NOT COMPANY OFFICE IS NOT COMPANY IS NOT COMPANY IS NOT COMPANY IS NOT COMPANY	S ONLY TO MOE ONTRACTICR (6) second) THE GH (7) ARC AND AND AND AND AND AND (7) ARC AND AND AND AND AND AND IS REQUIRED TO AND AND AND IS REQUIRED TO AND AND AND AND AND IS REQUIRED TO AND AND AND AND AND AND IS AND AND AND AND AND AND AND AND AND IS AND	DIFICATIONS OF C DER NO. AS DESCI MADE SET FORTH MITTER ADMINISTRATIVE CHANGES BITTY OF:	UNT:	SORDER ITEM 14. IN THE CONT ges is paying of COPI Nero Secular.)	RACTOR:	eviation date, etc.) BET
	DAMPROMISSION BATH AND A STATE	Treparent DOC #300011 UPC #3000110 UPC #30001100010000000000000000000000000000	S ONLY TO MOE ONTRACTICR (6) second) THE GH (7) ARC AND AND AND AND AND AND (7) ARC AND AND AND AND AND AND IS REQUIRED TO AND AND AND IS REQUIRED TO AND AND AND AND AND IS REQUIRED TO AND AND AND AND AND AND IS AND AND AND AND AND AND AND AND AND IS AND	DIFICATIONS OF C DER NO. AS DESCI MADE SET FORTH MITTER ADMINISTRATIVE CHANGES BITTY OF.	UNT: UNT: UNT: UNT: UNT: UNT: UNT:	CORDER TEM 14. IN THE CONT gas in paying of coopie coopie mare Reader,)	RACT ORC	enterior dans, etc.) BET te issuing office
	DAMPERIANCIA GATA, B SOCC 25.55 13. THIS ITI IT MOD NEE ONCERH IS BRUED PAR TIPM IL, PURSUART TO TH ITIMU IL, PURSUART TO TH INVESTMENT ACCOMPANY AMENOMENTANCOPICATION TE: IC: IC: IC: IC: IC: IC: IC: IC	Trepared DeC 4300H1 EM APPLIES IFIES THE C IFIES THE	S ONLY TO MOE ONTRACTICR (6) second) THE GH (7) ARC AND AND AND AND AND AND (7) ARC AND AND AND AND AND AND IS REQUIRED TO AND AND AND IS REQUIRED TO AND AND AND AND AND IS REQUIRED TO AND AND AND AND AND AND IS AND AND AND AND AND AND AND AND AND IS AND	DERIGATIONS OF CLOPER NO. AS DESCH	UNT: UNT: UNT: UNT: UNT: UNT: UNT:	CORDER TEM 14. IN THE CONT gas in paying of coopie coopie mare Reader,)	RACT ORC	enterior dans, etc.) BET te issuing office
	DAMPERIANCIA GATA, B SOCC 25.55 13. THIS ITI IT MOD NEE ONCERH IS BRUED PAR TIPM IL, PURSUART TO TH ITIMU IL, PURSUART TO TH INVESTMENT ACCOMPANY AMENOMENTANCOPICATION TE: IC: IC: IC: IC: IC: IC: IC: IC	Prepared Deck 3309M1 EM APPLIES IFIES THE C ENDER IS WORT OF IS AUXIMUM AND AND ENTERED INTO a sufficient of a sufficient of a sufficient of a sufficient of a sufficient of a sufficient of the document of protify	S ONLY TO MOC DONTRACTIONE development HED TO REFLECT THE "APA & 15000 IS required to sit is required to sit is required to sit of website heading. A TO TO TO	DERIGATIONS OF CLOSER NO. AS DESCH NEWSER SET FORMER MILITIA ADMINISTRATIVE CHANGES SETTY OF. TAL CONTRACT AMOR TAL CONTRACT AMOR A DEVICE AND A DEVICE AND A DEVICE AND A DEVICE AND A DEVICE AND A DEVICE AND A DEVICE THE AVAILABLE AND THE THE AVAILABLE AND THE THE AVAILABLE AND THE SET	UNT: UNT: UNT: UNT: UNT: UNT: UNT:	CIORDER TEM 14. IN THE CONT get in paying of coppi coppi nore fiscable.)	RACT ORC	et or phil)

- Any changes in the terms or conditions of the Contract, including the Statement of Work, changes in Key Personnel, or delivery schedule must be accomplished by a written modification.
- The contractor should submit their formal requests in writing to the Contracting Officer for review. The Contracting Officer will review the request, obtain recommendation from the COR and provide consent, decline, or request further information from the Contractor.



Key Personnel

 Prior to diverting from the individual identified as Key Personnel under Article G of the contract, the Contractor shall notify the CO in advance of replacing Key Personnel. The request should include sufficient information (CV including qualifications), to authorize replacement and avoid negative impact to the program/contract.

 No diversion shall be made by the Contractor without the written consent of the CO.

Invoice Submission and Payment

- The Government shall make payments, including invoice and contract financing payments, by electronic funds transfer (EFT).
- Payments on fixed price contracts may be made based on the satisfactory completion, receipt, and acceptance of contract deliverables.
- Payments on cost-reimbursement contracts may be made pursuant to receipt of proper invoices of allowable costs incurred which may be submitted no more frequently than on a monthly basis unless otherwise authorized by the Contracting Officer.
- For all contracts, final payment will not be made until all reports and deliverables included in the contract have been delivered and accepted by the Government.



Reporting Requirements/ Deliverable

Satisfactory performance of the final contract shall be deemed to occur upon performance of the work described in the Statement of Work in SECTION C of the contract and upon delivery and acceptance by the Contracting Officer, (and the COR), of items in accordance with the stated delivery schedule found in Article C. Reporting Requirements & Article F. Deliveries

Examples of some deliverables -

- **Technical Progress Reports**
- Monthly Progress Report
- ✓ Final Report

✓ Summary of Salient Results (to be submitted with the Final Report)

Other Reports/Deliverables

- ✓ NIH Small Business Innovation Research (SBIR) Program Life Cycle Certification
- Final Invention Statement



Evaluation of Contractor Performance (CPARS)

Article G. Post Award Evaluation Of Contractor Performance

- Interim (annual) and Final Evaluations of Contractor performance will be prepared accordance with FAR Subpart 42.15.
- Evaluation Factors:
 - Technical/ Quality of Product or Service
 - Cost Control
 - Schedule/ Timelines
 - Management / Business Relations
 - Regulatory Compliance
- All evaluations will be provided to the Contractor and will be permitted thirty days to review the document and to submit additional information or a rebutting statement.
- Copies of the evaluations, Contractor responses, and review comments, if any, will be retained, and may be used to support future award decisions.





Moving to Phase II and Fast Track

- Phase I Contractors, that did not get awarded a Fast Track contract, will be informed of the opportunity to apply for Phase II from the Awarding Components after (or close to) the expiration of the Phase I contract.
- Phase I awardees will be provided with the Phase II proposal submission requirements with the details on the due date, content, and submission requirements of the Phase II proposal.
- Only one Phase II award may result from a single Phase I SBIR contract.
- A Fast Track contracts are awards for Phase I with a contractual option for Phase II. The Government is not obligated to fund the Phase II portion unless and until the Awarding Component exercises that option at the end of the Phase I contract option.

U.S. Department of Health & Human Services Office of Inspector General

Preventing Fraud Waste and Abuse in your SBIR/STTR Award

Presented by: Jonelle Soeffing, Operations Officer

DEPARTMEN

HHS-OIG Mission

- Ol's mission is to protect the integrity of HHS programs. Ol conducts Criminal, Civil, Administrative investigations of fraud, waste, abuse and misconduct.
- Fraud, waste and abuse typically fall into one or more of three general categories:
 - Conflicts of Interest
 - Theft of government funds/Embezzlement
 - Failing to Properly Support the Use of Funds

HHS-OIG Mission

- Fraud: intentional or deliberate act to deprive another of property or money by deception or other unfair means.
- Waste: practices that, directly or indirectly, result in unnecessary costs, such as overusing services and misusing resources.
- Abuse: Intentional or unintentional, thoughtless or careless expenditure, consumption, mismanagement of government resources; Excessive or improper use of government resources, including position and authority.



Fraud Schemes

- False information on grant applications, progress reports, etc.
- Creating fictitious records: fabricated companies and invoices
- Using funds for unauthorized purposes
- Not doing any work
- Kickbacks
- PI outside employment
- Awardee company size misrepresentation

Specific examples of what NOT to do:

- Operate out of your residence (without authority)
- Use grant funds for personal expenses
- Pay others to do ALL the proposed research
- NOT pay institutions who did do the proposed work but still draw down the grant funds
- Lie to the awarding entity including on your biosketch

Fraud Awareness

Awareness of fraud is important, in order to safeguard Federal funds.

- Fraudsters utilize SBIR funds that may otherwise be given to legitimate awardees. Compliance with Federal Regulations, establishment of internal controls, and other compliance measures may reduce your risk.
- Use the grant money for what you said it would be used for - no more, no less
- Disclosure and communication with HHS Grants Officials is key.

Fraud Consequences

Criminal Prosecution:

18 USC 641 Criminal Embezzlement and Theft of Public Money

- Knowingly converting funds or items to your use without the authority to do so.
- Government must prove it was an intentional act.
- Criminal Penalties Prison, Fines, Restitution

18 USC 1001 False Statements

• Grant application signature and certifications, and in the quarterly financial statements made when drawing down funds.

Civil Prosecution:

31 USC 3729 False Claims

- Knowingly present, or cause to be presented, a false or fraudulent claim or payment or approval.
- Actual knowledge, reckless disregard or deliberate ignorance.
- Government does not need to prove fraudulent intent, preponderance of evidence.
- Triple damages plus penalties between \$5,500 to \$11,000 per offense.

Administrative Action:

- Civil Monetary Penalties
- Exclusion
- Suspension
- Debarment

HHS-OIG Case Examples

PRESS RELEASE



Two Biotech Firms And Their Co-Founder To Pay \$10 Million To Resolve Allegations Of Mischarging Federal Grants

Wednesday, December 21, 2022



For Immediate Release

U.S. Attorney's Office, Northern District of California



UM Researcher Falsifies Records in Federal Investigation

University of Montana

Report Fraud, Waste, & Abuse

PHONE: 1-800-447-8477 (1-800-HHS-TIPS)

TTY: 1-800-377-4950

ONLINE: oig.hhs.gov/fraud/hotline



U.S. Department of Health and Human Services Office of Inspector General



Q&A Session



Connect with SEED



Online http://seed.nih.gov/





@nihseed <u>https://twitter.com/nihseed</u>



Sign up for NIH and SEED updates: https://seed.nih.gov/subscribe

The NIH Guide for Grants and Contracts: http://grants.nih.gov/grants/guide/listserv.htm

